United Therapeutics (UTHR) Research & Development (2009 - 2026)

United Therapeutics has disclosed Research & Development across 18 years of filings, most recently posting $146.3 million for Q2 2026.

• In Q2 2026, Research & Development rose 9.18% year-over-year to $146.3 million; the TTM figure through Jun 2026 stood at $551.5 million (up 6.0% YoY), while the FY2025 annual figure was $550.0 million, up 14.35% from the prior year.
• Research & Development came in at $146.3 million for Q2 2026 at United Therapeutics, up from $138.2 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $151.4 million in Q4 2023 to a low of $66.1 million in Q3 2022.
• Average Research & Development over 5 years is $113.7 million, with a median of $115.8 million recorded in 2024.
• Year-over-year, Research & Development plunged 77.28% in 2022 and jumped 61.24% in 2023.
• Over 5 years, Research & Development stood at $93.9 million in 2022, then jumped by 61.24% to $151.4 million in 2023, then declined by 11.62% to $133.8 million in 2024, then advanced by 4.26% to $139.5 million in 2025, then gained by 4.87% to $146.3 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $146.3 million in Q2 2026, $138.2 million in Q1 2026, and $139.5 million in Q4 2025.